Cheung Laboratories, Inc. (CLI) - 10-K Summary
Business Context and Reporting Period
Company: Cheung Laboratories, Inc. (CLI)
Reporting Period: Fiscal year ended September 30, 1996
Business Overview: CLI develops and markets minimally invasive medical devices utilizing microwave thermotherapy for cancer and Benign Prostatic Hyperplasia (BPH). The Company's primary commercial product is the Microfocus 1000 (FDA approved for surface cancers). CLI is currently in the engineering and clinical trial stages for new technologies, including the Microfocus APA (for deep-seated tumors) and an enhanced BPH system incorporating compression technology. The Company recently terminated diversification efforts in cosmetics and industrial plumbing to refocus on its core medical device business.
Key Financial Metrics
| Metric | Fiscal 1996 | Fiscal 1995 |
|---|---|---|
| Total Revenues | $74,006 | $157,618 |
| Cost of Product Sales | $64,406 | $67,350 |
| Gross Profit | $9,600 | $90,268 |
| Operating Loss | $(1,422,782) | $(1,298,123) |
| Net Loss | $(1,933,471) | $(1,397,317) |
| Net Loss Per Share | $(0.049) | $(0.060) |
| Cash and Equivalents (End of Period) | $246,931 | $7,238 |
| Working Capital | $(646,754) | $(1,101,136) |
| Accumulated Deficit | $(12,211,633) | $(10,278,162) |
| Total Debt (Current + Long-Term) | $1,544,726 | $929,369 |
Note: Debt includes $1,205,000 in senior secured convertible notes issued in July 1996 and various related-party notes.
Material Changes vs. Prior Period
- Revenue Decline: Product sales dropped 53% to $74,006 due to a strategic shift away from sales efforts toward technology development and the termination of non-core business ventures.
- Increased R&D: Research and development expenses surged to $94,012 (from $18,546) to fund the integration of Adaptive Phased Array (APA) and MMTC compression technologies.
- Debt Financing: The Company issued $1,205,000 in senior secured convertible notes to fund operations, increasing total liabilities significantly.
- Asset Restructuring: The Company rescinded its investment in Ardex Equipment, LLC, converting the equity interest into a $400,000 promissory note. It also entered into a redemption agreement to terminate its investment in Aestar Fine Chemical Company.
Guidance, Outlook, and Risks
Outlook: Management anticipates continued operating losses in the near term. Profitability is contingent upon obtaining FDA approval for new technologies (Microfocus APA and enhanced BPH systems) and successfully commercializing them. The Company expects to rely on revenue-sharing models with treatment centers rather than direct equipment sales.
Liquidity Risk: The Company explicitly states that existing capital resources are not adequate to fund operations for the next twelve months. It is dependent on raising additional capital through equity or debt financing. Failure to secure funding could force the Company to delay or eliminate operations.
Regulatory Risk: Commercialization of the Microfocus System (BPH) and Microfocus APA (Cancer) requires Investigational Device Exemptions (IDE) and Premarket Approvals (PMA) from the FDA. There is no assurance these will be granted.
Going Concern: The independent auditors have issued a "Going Concern" opinion, citing substantial doubt about the Company's ability to continue operations due to recurring losses and working capital deficits.
Subsequent Event: On October 23, 1996, the Company redeemed 16,000,000 shares of common stock from a major investor (Mr. Gao) in exchange for the return of an $8,000,000 investment in Aestar. If adjusted for this transaction, the Company's stockholders' equity would have been negative $(1,284,126) as of September 30, 1996.
Investor Verification Checklist
- Cash Runway: Verify the Company's ability to raise the necessary capital to survive the next 12 months, given the explicit statement of insufficient funds.
- Stock Redemption Obligation: Confirm the status of the $2,160,000 payment due to Mr. Gao by March 31, 1997, to redeem the remaining 4,000,000 shares.
- FDA Progress: Monitor the status of the IDE applications for the Microfocus System and Microfocus APA, as commercialization is impossible without these approvals.
- Debt Maturity: Review the terms of the $1,205,000 senior secured convertible notes, which mature on December 31, 1997, or upon the next private offering.
- Equity Dilution: Assess the impact of outstanding options and warrants (approx. 6.2 million shares) and the potential dilution from future financing needs.